Keratinocyte expression of inflammatory mediators plays a crucial role in substance P-induced acute and chronic pain

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Wei, Tzuping ^a   Guo, Tian Zhi ^a   Li, Wen Wu ^a,b   Hou, Saiyun ^a   Kingery, Wade S ^a   Clark, John D ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LANEPITANT; MUMAB 911; NERVE GROWTH FACTOR ANTIBODY; NERVE GROWTH FACTOR BETA SUBUNIT; NEUROKININ 1 RECEPTOR; SUBSTANCE P; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAST REMOVAL; CELL PROLIFERATION; CHRONIC PAIN; COMPLEX REGIONAL PAIN SYNDROME; CONTROLLED STUDY; DOSE RESPONSE; FRACTURE IMMOBILIZATION; HEAT SENSATION; KERATINOCYTE; MALE; MICRO-COMPUTED TOMOGRAPHY; NOCICEPTION; NONHUMAN; OSTEOLYSIS; PAIN; PAW EDEMA; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TIBIA FRACTURE; TISSUE LEVEL;

EID: 84866762789     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-181     Document Type: Article

References (42)

1. Sarangi PP, Ward AJ, Smith EJ, Staddon GE, Atkins RM. Algodystrophy and osteoporosis after tibial fractures. J Bone Joint Surg Br 1993, 75:450-452.
2. Guo TZ, Offley SC, Boyd EA, Jacobs CR, Kingery WS. Substance P signaling contributes to the vascular and nociceptive abnormalities observed in a tibial fracture rat model of complex regional pain syndrome type I. Pain 2004, 108:95-107. 10.1016/j.pain.2003.12.010, 15109512.
3. Groeneweg JG, Huygen FJ, Heijmans-Antonissen C, Niehof S, Zijlstra FJ. Increased endothelin-1 and diminished nitric oxide levels in blister fluids of patients with intermediate cold type complex regional pain syndrome type 1. BMC Musculoskelet Disord 2006, 7:91. 10.1186/1471-2474-7-91, 1693561, 17137491.
4. Sabsovich I, Guo TZ, Wei T, Zhao R, Li X, Clark DJ, Geis C, Sommer C, Kingery WS. TNF signaling contributes to the development of nociceptive sensitization in a tibia fracture model of complex regional pain syndrome type I. Pain 2008, 137:507-519. 10.1016/j.pain.2007.10.013, 2529181, 18035493.
5. Sabsovich I, Wei T, Guo TZ, Zhao R, Shi X, Li X, Yeomans DC, Klyukinov M, Kingery WS, Clark JD. Effect of anti-NGF antibodies in a rat tibia fracture model of complex regional pain syndrome type I. Pain 2008, 138:47-60. 10.1016/j.pain.2007.11.004, 2538487, 18083307.
6. Wei T, Sabsovich I, Guo TZ, Shi X, Zhao R, Li W, Geis C, Sommer C, Kingery WS, Clark DJ. Pentoxifylline attenuates nociceptive sensitization and cytokine expression in a tibia fracture rat model of complex regional pain syndrome. Eur J Pain 2009, 13:253-262. 10.1016/j.ejpain.2008.04.014, 2673487, 18554967.
7. Li WW, Sabsovich I, Guo TZ, Zhao R, Kingery WS, Clark JD. The role of enhanced cutaneous IL-1beta signaling in a rat tibia fracture model of complex regional pain syndrome. Pain 2009, 144:303-313. 10.1016/j.pain.2009.04.033, 2743308, 19473768.
8. Li WW, Guo TZ, Li XQ, Kingery WS, Clark JD. Fracture induces keratinocyte activation, proliferation, and expression of pro-nociceptive inflammatory mediators. Pain 2010, 151:843-852. 10.1016/j.pain.2010.09.026, 2972360, 20934254.
9. Weber M, Birklein F, Neundorfer B, Schmelz M. Facilitated neurogenic inflammation in complex regional pain syndrome. Pain 2001, 91:251-257. 10.1016/S0304-3959(00)00445-0, 11275381.
10. Oyen WJ, Arntz IE, Claessens RM, Van der Meer JW, Corstens FH, Goris RJ. Reflex sympathetic dystrophy of the hand: an excessive inflammatory response?. Pain 1993, 55:151-157. 10.1016/0304-3959(93)90144-E, 8309706.
11. Leis S, Weber M, Isselmann A, Schmelz M, Birklein F. Substance-P-induced protein extravasation is bilaterally increased in complex regional pain syndrome. Exp Neurol 2003, 183:197-204. 10.1016/S0014-4886(03)00163-8, 12957502.
12. Leis S, Weber M, Schmelz M, Birklein F. Facilitated neurogenic inflammation in unaffected limbs of patients with complex regional pain syndrome. Neurosci Lett 2004, 359:163-166. 10.1016/j.neulet.2004.02.025, 15050689.
13. Weidner C, Klede M, Rukwied R, Lischetzki G, Neisius U, Skov PS, Petersen LJ, Schmelz M. Acute effects of substance P and calcitonin gene-related peptide in human skin-a microdialysis study. J Invest Dermatol 2000, 115:1015-1020. 10.1046/j.1523-1747.2000.00142.x, 11121135.
14. Wei T, Li WW, Guo TZ, Zhao R, Wang L, Clark DJ, Oaklander AL, Schmelz M, Kingery WS. Post-junctional facilitation of Substance P signaling in a tibia fracture rat model of complex regional pain syndrome type I. Pain 2009, 144:278-286. 10.1016/j.pain.2009.04.020, 2706925, 19464118.
15. Guo TZ, Wei T, Kingery WS. Glucocorticoid inhibition of vascular abnormalities in a tibia fracture rat model of complex regional pain syndrome type I. Pain 2006, 121:158-167. 10.1016/j.pain.2005.12.022, 16472917.
16. Paus R, Heinzelmann T, Robicsek S, Czarnetzki BM, Maurer M. Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation in situ. Arch Dermatol Res 1995, 287:500-502. 10.1007/BF00373436, 7542862.
17. Tanaka T, Danno K, Ikai K, Imamura S. Effects of substance P and substance K on the growth of cultured keratinocytes. J Invest Dermatol 1988, 90:399-401. 10.1111/1523-1747.ep12456487, 2450147.
18. Saade NE, Massaad CA, Ochoa-Chaar CI, Jabbur SJ, Safieh-Garabedian B, Atweh SF. Upregulation of proinflammatory cytokines and nerve growth factor by intraplantar injection of capsaicin in rats. J Physiol 2002, 545:241-253. 10.1113/jphysiol.2002.028233, 2290671, 12433964.
19. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110. 10.1016/0304-3959(83)90201-4, 6877845.
20. Hongo JS, Laramee GR, Urfer R, Shelton DL, Restivo T, Sadick M, Galloway A, Chu H, Winslow JW. Antibody binding regions on human nerve growth factor identified by homolog- and alanine-scanning mutagenesis. Hybridoma 2000, 19:215-227. 10.1089/02724570050109611, 10952410.
21. Halvorson KG, Kubota K, Sevcik MA, Lindsay TH, Sotillo JE, Ghilardi JR, Rosol TJ, Boustany L, Shelton DL, Mantyh PW. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 2005, 65:9426-9435. 10.1158/0008-5472.CAN-05-0826, 16230406.
22. Sevcik MA, Ghilardi JR, Peters CM, Lindsay TH, Halvorson KG, Jonas BM, Kubota K, Kuskowski MA, Boustany L, Shelton DL, Mantyh PW. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 2005, 115:128-141. 10.1016/j.pain.2005.02.022, 15836976.
23. Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A. Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain 2005, 116:8-16. 10.1016/j.pain.2005.03.039, 15927377.
24. Gitter BD, Bruns RF, Howbert JJ, Waters DC, Threlkeld PG, Cox LM, Nixon JA, Lobb KL, Mason NR, Stengel PW, et al. Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin 1) receptor antagonist. J Pharmacol Exp Therapeut 1995, 275:737-744.
25. Hipskind PA, Howbert JJ, Bruns RF, Cho SSY, Crowell TA, Foreman MM, Gehlert DR, Iyengar S, Johnson KW, Krushinski JH, Li DL, Lobb KL, Mason NR, Muehl BS, Nixon JA, Phebus LA, Regoli D, Simmons RM, Threlkeld PG, Waters DC, Gitter BD. 3-Aryl-1,2,-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists. J Med Chem 1996, 39:736-748. 10.1021/jm950616c, 8576917.
26. Iyengar S, Hipskind PA, Gehlert DR, Schober D, Lobb KL, Nixon JA, Helton DR, Kallman MJ, Boucher S, Couture R, Li DL, Simmons RM. LY303870, a centrallyactive neurokinin-1 antagonist with a long duration of action. J Pharmacol Exp Ther 1997, 280:774-785.
27. Kingery WS, Davies MF, Clark JD. A substance P receptor (NK1) antagonist can reverse vascular and nociceptive abnormalities in a rat model of complex regional pain syndrome type II. Pain 2003, 104:75-84. 10.1016/S0304-3959(02)00467-0, 12855316.
28. Wojtowicz JM, Kee N. BrdU assay for neurogenesis in rodents. Nat Protoc 2006, 1:1399-1405. 10.1038/nprot.2006.224, 17406427.
29. Schinkel C, Gaertner A, Zaspel J, Zedler S, Faist E, Schuermann M. Inflammatory mediators are altered in the acute phase of posttraumatic complex regional pain syndrome. Clin J Pain 2006, 22:235-239. 10.1097/01.ajp.0000169669.70523.f0, 16514322.
30. de Mos M, Huygen FJ, Stricker BH, Dieleman JP, Sturkenboom MC. The association between ACE inhibitors and the complex regional pain syndrome: Suggestions for a neuro-inflammatory pathogenesis of CRPS. Pain 2009, 142:218-224. 10.1016/j.pain.2008.12.032, 19195784.
31. Kramer HH, He L, Lu B, Birklein F, Sommer C. Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase. Neurobiol Dis 2009, 35:177-183. 10.1016/j.nbd.2008.11.002, 19084065.
32. Sahbaie P, Shi X, Guo TZ, Qiao Y, Yeomans DC, Kingery WS, Clark JD. Role of substance P signaling in enhanced nociceptive sensitization and local cytokine production after incision. Pain 2009, 145:341-349. 10.1016/j.pain.2009.06.037, 2746201, 19660865.
33. Dionne RA, Max MB, Gordon SM, Parada S, Sang C, Gracely RH, Sethna NF, MacLean DB. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther 1998, 64:562-568. 10.1016/S0009-9236(98)90140-0, 9834049.
34. Kingery WS. Role of neuropeptide, cytokine, and growth factor signaling in complex regional pain syndrome. Pain Med 2010, 11:1239-1250. 10.1111/j.1526-4637.2010.00913.x, 20704672.
35. Malik-Hall M, Dina OA, Levine JD. Primary afferent nociceptor mechanisms mediating NGF-induced mechanical hyperalgesia. Eur J Neurosci 2005, 21:3387-3394. 10.1111/j.1460-9568.2005.04173.x, 16026476.
36. Cattaneo A. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. Curr Opin Mol Ther 2010, 12:94-106.
37. Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, Brown MT. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010, 363:1521-1531. 10.1056/NEJMoa0901510, 20942668.
38. Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthr Cartil 2011, 19:639-646. 10.1016/j.joca.2011.01.009, 21251985.
39. Katz N, Borenstein DG, Birbara C, Bramson C, Nemeth MA, Smith MD, Brown MT. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain 2011, 152:2248-2258. 10.1016/j.pain.2011.05.003, 21696889.
40. Zhao P, Barr TP, Hou Q, Dib-Hajj SD, Black JA, Albrecht PJ, Petersen K, Eisenberg E, Wymer JP, Rice FL, Waxman SG. Voltage-gated sodium channel expression in rat and human epidermal keratinocytes: evidence for a role in pain. Pain 2008, 139:90-105. 10.1016/j.pain.2008.03.016, 18442883.
41. Hou Q, Barr T, Gee L, Vickers J, Wymer J, Borsani E, Rodella L, Getsios S, Burdo T, Eisenberg E, Guha U, Lavker R, Kessler J, Chittur S, Fiorino D, Rice F, Albrecht P. Keratinocyte expression of calcitonin gene-related peptide beta: implications for neuropathic and inflammatory pain mechanisms. Pain 2011, 152:2036-2051. 10.1016/j.pain.2011.04.033, 21641113.
42. Urban LA, Fox AJ. NK1 receptor antagonists-are they really without effect in the pain clinic?. Trends Pharmacol Sci 2000, 21:462-464. author reply 465, 10.1016/S0165-6147(00)01578-9, 11229417.